Amplyx Pharmaceuticals Gets $40.5M For Anti Fungal Drugs

San Diego-based Amplyx Pharmaceuticals announced this morning that it has raised $40.5M in a Series B funding round. The company, which is developing treatments for fungal infections, said the funding was led by RiverVest Venture Partners, and also included New Enterprise Associates, BioMed Ventures and individuals. Apmlyx has compounds in both Phase 1 and Phase 2 trials. The company is developing a broad-spectrum antifungal agent to treat life threatening fungal infections. Niall O'Donnell, of RiverVest Venture Partners, and Ed Mathers of New Enterprise Associates have both joined the company's board with the funding.